Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
Hutchmed
Rain Oncology Inc
Hutchmed
Hoffmann-La Roche
Amgen
National Cancer Institute (NCI)
INSYS Therapeutics Inc